RE:RE:RE:Everybody Be QuietIf they meet TD's (post Brexit) EBITDA targets the company is mad cheap. It's easy to see those targets being met given the fact that they added an additional drug every 10 days in Q1 and continue to roll out a drug every 2 weeks (on average). The EBITDA from these drugs could possibly bring them within pre Brexit 2016 EBITDA guidance despite the 25M probable loss from the weak pound. If the debt comes down by 100M and they squeak into the low end of 2016 guidance, that would be a really good showing.
GoldBug024 wrote:
This is a good company back to 60 by years end. Not telling anyone to buy or sell. Just my opinion.